During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in San Diego, findings from the pivotal, Phase III MANIFEST-2 trial of pelabresib and ruxolitinib versus placebo and ruxolitinib in JAK inhibitor treatment-naïve patients with myelofibrosis were presented (Abstract 628).
December 11, 2023
Read moreIn a comprehensive investigation aimed at understanding the prognostic implications of dynamic thrombocytopenia in patients with myelofibrosis (MF), researchers from the Seoul St. Mary's Hematology Hospital have uncovered crucial genetic and immunologic factors associated with this phenomenon. The study findings were presented at the 65th ASH Annual Meeting and Exposition (Abstract 1835).
December 11, 2023
Read moreNew findings showed that PXS-5505, a pan-LOX inhibitor, is well-tolerated among patients with primary, post-polycythemia vera or post-essential thrombocythemia myelofibrosis with no dose-limited toxicity or serious treatment-related adverse events. This data was recently presented during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in San Diego (Abstract 625).
December 11, 2023
Read moreMyelofibrosis is a somewhat rare hematologic malignancy that can lead to scarring of the patient’s bone marrow. It impacts patients with low blood counts, enlarged spleen, and symptoms. This scarring can hinder hematopoiesis, resulting in anemia. Prior to 2011, there were no approved therapies for this condition.
December 10, 2023
Read moreA combination of navitoclax and ruxolitinib led to a clinically significant reduction in spleen size in patients with untreated myelofibrosis (MF), according to the results of a randomized, double-blind, placebo-controlled, multicenter, international Phase III trial.
December 10, 2023
Read moreIn a global effort involving collaboration among European, U.S., and Latin American medical centers, a breakthrough has emerged regarding the role of splenic irradiation as a preliminary treatment approach for patients with myelofibrosis anticipating hematopoietic cell transplantation (HCT).
December 10, 2023
Read moreA novel artificial intelligence (AI) model can quickly distinguish between prefibrotic primary myelofibrosis (PMF) and essential thrombocythemia (ET) with high accuracy in distinct clinical cohorts.
December 9, 2023
Read moreThe targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.
December 9, 2023
Read moreA new study from researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, along with collaborating organizations, provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.
December 9, 2023
Read more